Cloning of HBsAg-encoded genes in different vectors and their expression in eukaryotic cells

1-1-2003

Shan Qin
University of Central Florida

Hong Tang

Lian-San Zhao

Fang He

Yong Lin

See next page for additional authors

Find similar works at: https://stars.library.ucf.edu/facultybib2000

University of Central Florida Libraries http://library.ucf.edu

Recommended Citation

Qin, Shan; Tang, Hong; Zhao, Lian-San; He, Fang; Lin, Yong; Liu, Li; and He, Xiao-Mei, "Cloning of HBsAg-encoded genes in different vectors and their expression in eukaryotic cells" (2003). Faculty Bibliography 2000s. 3974.
https://stars.library.ucf.edu/facultybib2000/3974

This Article is brought to you for free and open access by the Faculty Bibliography at STARS. It has been accepted for inclusion in Faculty Bibliography 2000s by an authorized administrator of STARS. For more information, please contact lee.dotson@ucf.edu.
Cloning of HBsAg-encoded genes in different vectors and their expression in eukaryotic cells

Shan Qin, Hong Tang, Lian-San Zhao, Fang He, Yong Lin, Li Liu, Xiao-Mei He

Shan Qin, Hong Tang, Lian-San Zhao, Fang He, Yong Lin, Li Liu
Key Laboratory for Molecular Biology of Infectious Diseases of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China
Xiao-Mei He
Analytical and Testing Center, Sichuan University, Chengdu 610064, Sichuan, China
Shan Qin
Center for Discovery of Drugs and Diagnostics, Biomolecular Science Center, University of Central Florida. 12722 Research Parkway, Orlando, Florida 32826. USA

Supported by the National Science Foundation of China, No. 39670670

Correspondence to: Dr Shan Qin, Key Laboratory for Molecular Biology of Infectious Diseases of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.

Telephone: +86-28-5242650
Received: 2001-09-14 Accepted: 2001-10-26

INTRODUCTION
Hepatitis B virus (HBV) infection is epidemic worldwide[1-3]. Unfortunately, there are no satisfactory drugs to cure HBV-related diseases, and the only way to control the epidemic is through vaccination[4-6]. Great efforts have been made to develop more successful vaccines than those currently available to prevent or to treat HBV infection. The newest approach is genetic immunization. This involves the transfer of a viral gene into host somatic cells by a plasmid vector, with subsequent endogenous production and intracellular processing of the virus’ structural proteins into small peptides. The processed peptides eventually induce a broad-based immune response[7-11]. Hepatitis B virus surface antigen consists of S (small surface), MS (medium surface, S+preS), and LS (large surface, S+preS+preS) HBsAg molecules. We have reported that DNA vaccine expressing HBsAg S molecule induced humoral and cellular immune responses against HBsAg[12,13]. Because the preS antigen is necessary for HBV to penetrate the cell membrane of the host, vaccines containing the preS antigen are more effective. Hence, we constructed a series of plasmids encoding small (S), medium (M), or large (L) envelope proteins of HBsAg utilizing different promoters. In addition, the expression levels of these recombinant plasmids were evaluated, in order to choose a better vector for designing future DNA vaccines.

MATERIALS AND METHODS
Gene fragments expressing S, MS, LS, and preS1S proteins
Plasmid pHBH4 (containing the adr subtype of HBV genome DNA) was used as a template to amplify S, preS2, and preS1S fragments. The following primers were used: the forward primers: SF (nt 28-41), 5’- GCG AAT TCT AGC TTA TCG CTT AGG ATC CAA TCG -3’ and SR (nt 705-693): GCG CGG CCG TAT TCG GAT AC -3’. The reverse primer was: SR (nt 705-693): GCG CGG CCG TAT TCG GAT AC -3’. The primers contain a flanking sequence having endonuclease enzyme sequence

RESULTS: Fragments with anticipated size were harvested after PCR. After recombination and screening, the sequences of the inserted segments in the recombinants were confirmed to be S, preS2, preS1-preS2S and preS1S encoding genes, determined by sequencing. The results of Western-blot hybridization were positive for the anticipated proteins. Among them, pRC/CMV-S or pRC/CMV-MS demonstrated the highest expressing their respective antigen.

CONCLUSION: Eight recombinant plasmids expressing S, M, L or preS1S proteins are obtained. For hepatitis surface antigen expression in eukaryotic cells, the vector pRC/CMV is superior to pSG5UTPL/Flag, and pRC/CMV-S and pRC/CMV-MS are the most efficient in the pRC/CMV clones. SP2/0 cells stably expressing HBsAg are established, and may be used as target cells for evaluating the CTL activity of a DNA vaccine in vitro.
for the convenience of clone manipulation.

To obtain a unique fragment containing the S and preS1 gene, overlap extension PCR was used. The forward primer (S-SF) is complementary to the beginning of the S gene and to the end of preS1 gene, while the reverse primer (S-SR) is complementary to the end of the preS1 gene and the beginning of the S gene (Figure 1). Using pBHB, as a template, and the S-SF/SR and S-F/preS-S-R primers, the resultant PCR product contained the 3' end of preS1 gene followed by the complete S gene sequences that the two PCR fragments contained complementary ends. When these fragments were consequently used as templates and S-F/SR primers, only the preS3-S was amplified.

\[
\text{S-SF (5') } \quad \text{CAT CCT CAG GGC ATG GAG AAC ACA (nt3065-3076)} \quad \text{S (nt28-39)} \\
\text{S-SIR (5') } \quad \text{TGT GTT CTC CAT GGC CTG AGG ATG (nt39-28)} \quad \text{preS1 (nt3076-3065)}
\]

**Figure 1** Primers designed for Overlap-Extension PCR.

**Recombinant plasmids construction**

The PCR fragments and plasmid vector pRc/CMV (containing the CMV promoter, Invitrogen, USA) were cleaved by HindIII/NotI (Bio-Lab, USA), while the PCR fragments and plasmid vector pSG5UTPL/Flag (containing SV40 promoter) were cleaved by BamHI/EcoRI (Bio-Lab, USA). The cleaved products were ligated using T4 DNA ligase. *E.coli* XLBlue1 was transformed using the ligated products and screened for the positive clones containing the inserted fragments, which was performed by colony-PCR techniques. The positive colonies were amplified, extracted, purified, and identified by endo-nuclease cleavage. The sequences of the inserted fragments were confirmed by sequencing with Nucleic Acid Auto-Analysis (TYPE 373A).

**Transient expression in vitro**

The extracted recombinant plasmids were purified by CsCl/ethidium bromide equilibrium centrifugation. SP2/0 cells (myeloma cells from inbred BALB/c mice) were transfected with purified plasmids by an amended calcium chloride method as described elsewhere. Two days later, the cells were collected in LAC buffer (20 mmol·L\(^{-1}\) Hapes pH 7.9, 400 mmol·L\(^{-1}\) NaCl, 1 mmol·L\(^{-1}\) EDTA, 9 mmol·L\(^{-1}\) CHAPS, 250 ml·L\(^{-1}\) glycerol) containing 1/200V 0.5 mol·L\(^{-1}\) EDTA, 5 g·L\(^{-1}\) DTT, 2.5 mmol·L\(^{-1}\) EDTA, 5 g·L\(^{-1}\) Apotinine, 5 g·L\(^{-1}\) Leupetine and 0.2 mol·L\(^{-1}\) PMSF, and lysed by sonication (Ubra-Cell, Sonics & Materials, USA). Supernatants were collected and analyzed as follows: proteins were separated by 120 g·L\(^{-1}\) SDS-polyacrylamide gel electrophoresis, and transferred to PVDF membranes (Millipore, USA), followed by blocking for 2 h in PBS containing 50 g·L\(^{-1}\) nonfat dry-milk at room temperature. To detect HBsAg, the membranes were first incubated with mono-clone anti-HBs antibody (BioGenex, USA) at 1:1 000 dilution and conjugated antibodies were detected with horseradish peroxidase-labeled multi-linker antibodies (BioGenex, USA) at a dilution of 1:300. The blots were visualized by chemiluminescence reactions (Luminol and Iodophenol, Fluka).

**Long-term transfected cell strains**

After the transient in vitro expression, the plasmids demonstrating a high level of expression were chosen to permanently transfect SP2/0 cells. After 2 d of transfection, fresh cultural medium containing 200 mg·L\(^{-1}\) G418 (at this concentration, there were no viable SP2/0 cells after 2 w in preliminary studies) was added in order to grow the cells under G418 pressure. The media was refreshed every 3 to 5 d. 2w later, cells forming colonies were chosen using a light microscope, and subcultured under G418 pressure. After 30 generations, the DNA was extracted following the protocols described elsewhere and detected the HBV S gene by dot-blot hybridization (Dig-probe of HBV S was prepared in our laboratory, Dig-labeling Kit from Roche Company). HBsAg in the culture media and supertant of cell lysates were detected by ELISA ( Kits from SABC), HBsAg in the cells by immunocytochemistry. Presence of the plasmid was detected by *in situ* hybridization with the corresponding probe (labeled in our laboratory, Dig-label kit from Roche Company). The cells containing the HBV S gene and the HBsAg were chosen as long-term expression cell strains and stored in liquid nitrogen for further use as the target cells for evaluation of CTL activity after DNA immunization.

**RESULTS**

**Construction of recombinant plasmids**

DNA fragments of 0.72kb, 0.88kb, and 1.24kb were generated by PCR methods (pBHB, template and SF/SR, S/F/SR, S/FSR primers). The length of these fragments corresponded to the length of S, MS, and LS genes. When the PCR product primed by S/F/S-S-R and S-SF/SR was used as templates (overlap extension PCR), a 1.02kb DNA fragment, equal to the length of preS, S was obtained. After cleavage by Hind III/Not I, S, MS, LS and preS, S genes were inserted into a multiple cloning site downstream of the CMV promoter in pRc/CMV, while the fragments cleaved by BamH/EcOri were inserted into multiple cloning site downstream of the SV40 promoter in pSG5UTPL/Flag. *E.coli* XLBlue1 cells were transformed separately with the series 8 recombinant plasmids, and cultured in LB containing ampicillin. PCR was performed on colonies, and 0.72kb, 0.88kb, 1.24kb, and 1.02kb fragments were obtained. When these PCR products were cleaved by restriction enzymes Hind III/Not I (pRc/CMV as vector) or BamH/EcOri (pSG5UTPL/Flag as vector), the anticipated DNA bands were obtained. We have constructed CMV promoter controlled recombinant plasmids: pCMV-S, pCMV-MS, pCMV-LS, pCMV-S-S; and SV40 promoter controlled recombinant plasmids: pSG5Flag-S, pSG5Flag-MS, pSG5Flag-LS, pSG5Flag-S-S. KOZAK sequences (CACC) were placed before the initiation code of all recombinant plasmids to enhance the efficiency of protein expression. The sequences of the inserted fragments of all 8 plasmids were identical to HBV-S, MS, LS and preS, S genes, confirmed by following sequencing.

**Transient expression**

After SP2/0 cells were transfected with recombinant plasmids above, the supernatants of lysed cells were run on SDS-PAGE and Western-Blot, all were positive for the anticipated bands, while the SP2/0 cells not transfected with the recombinants were negative for any HBsAg antigen. Among them, pRc/CMV-S and pRc/CMV-S-S demonstrated the highest expression.

**Construction of long-term expression cell strains**

pRc/CMV-S and pRc/CMV-S-S were used to transfact SP2/0 cells. The transfected cells grew in clusters under the selection pressure of G418. After 2 mo, 10 strains of SP2/0-pRc/CMV-S and 16 strains of SP2/0-pRc/CMV-S,S continued to grow well in G418-containing medium, while SP2/0 cells not transfected with recombinant plasmid died within 2 wk. Of the G418 resistant monoclonem cells, 3 strains of SP2/0-pRc/CMV-S and 4 strains of SP2/0-pRc/CMV-S,S were positive for HBsAg in the supernatants of sonicated cells. The HBsAg was detected by ELISA. They were also positive for the protein...
bands when detected by Western-Blot. Cytosolic HBsAg was detected by immunochemistry. The 7 cell strains above were also positive for pRc/CMV-S or pRc/CMV-S,S when detected by in situ hybridization.

**DISCUSSION**

DNA immunization involves the recombination of the genes of interest with the selected eukaryotic expression plasmid/vector and the transfer of the recombinant plasmid into muscle or skin cells of the host, with a subsequent induction of specific immune responses.[16-20] DNA immunization is attractive for its advantages over traditional vaccines, and is discussed in elsewhere.[22-24] We have reported that HBV DNA vaccine NV-HBs could express HBsAg in muscle cells after injecting into mouse muscle, followed by the induction of an immune response, including the switch over of anti-HBs production in peripheral blood.[25,26]

HBsAg-encoded genes include S, preS1, and preS2. All the proteins expressed by these genes are antigenic. The elicited response is strongest with preS1 and preS2. The titer of preS antibody in rabbits immunized with preS protein is 400 times greater than that of S antibody in rabbits immunized with S protein. In addition, some mice are non-responsive to S protein of HBV, which is determined by an allele of H2 gene. Vaccines containing HBV preS, and/or preS1 antigen may alter this inherited non-responsive state, inducing anti-HBs in mice which were previously immunized with vaccines only containing S. Moreover, preS proteins are necessary in order for HBV to infect hepatocytes. preS1 protein can bind hepatocytes specifically while preS1 can bind hepatocytes through PHSA (polymerase human serum albumin). Because of the importance of HBV preS proteins, we constructed plasmids, which can be used for DNA vaccines containing the preS1 and/or preS2 genes. Several plasmids were constructed by different promoters in order to compare their expression efficiency. All these recombinant plasmids demonstrated expression in SP2/0 cells, while the vector pRC/CMV was the most effective, with the highest expression demonstrated as pRC/CMV-S and pRC/CMV-S,S. pRC/CMV-S and pRC/CMV-S,S may be used as good candidates for DNA immunization. Their efficacy in inducing immune responses is still in experimental process.

Long-term expression cell strains transfected with pRC/CMV-S or pRC/CMV-S,S were established in our experiment through selection with G418 more than 30 generations. The cell lines SP2/0-pRC/CMV-S and SP2/0-pRC/CMV-S,S can express HBsAg S protein or S,S protein effectively and may be used as target cells for CTL test in the study of DNA immunization for HBV in the near future.

**ACKNOWLEDGEMENTS**

We are grateful to Prof. Senshi Murukami, Kanazawa University in Japan, for generous gift of plasmid pBHB4 and plasmid vector pSGSUTPL. The authors thank Kathleen N from Biomolecular Science Center of University of Central Florida for her reviewing of the manuscript.

**REFERENCES**

1. Christensen PB, Krarup HB, Niesters HG, Norder H, Schaffalitzky de Muckadell OB, Jeune B, Georgsen J. Outbreak of Hepatitis B among injecting drug users in Denmark. J Clin Virol 2001; 1: 133-141
2. Yerly S, Quadri R, Negro F, Barke KP, Chezeaux J, Burgisser P, Siegrist CA, Perrin L. Nosocomial outbreak of multiple bloodborne viral infections. J Infect Dis 2001; 3: 369-372
3. Whalley SA, Murray JM, Brown D, Webster GJ, Emery VC, Dulshko GM, Perelson AS. Kinetics of acute hepatitis B virus infection in humans. J Exp Med 2001; 7: 847-854
4. Lin OS, Kefee EB. Current treatment strategies for chronic hepatitis B and C. Annu Rev Med 2001; 52: 29-49
5. Vryheid RE, Yu ES, Mehta KM, McGhee J. The declining prevalence of hepatitis B virus infection among Asian and Pacific Islander children. Asian Am Pac Isl J Health 2001; 2: 162-178
6. Mler P, Telero C, Zoulmin F. Current management strategies for hepatitis B in the elderly. Drugs Aging 2001; 10: 725-735
7. von Reyn CF, Vuola JM. New vaccines for the prevention of tuberculosis. Clin Infect Dis 2002; 4: 465-474
8. Riedl P, El-Kholy S, Reimann J, Schirmeck R. Priming biologically active antibody responses against an isolated, conformational viral epitope by DNA vaccination. J Immunol 2002; 3: 1251-1260
9. Heinen PP, Rijswijk FA, De Boer-Luitjze EA, Bianchi AT. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 2002; 8: 1851-1859
10. Coban C, Ishij K, Sullivan DJ, Kumar N. Purified malaria pigment (hemozoin) enhances dendritic cell maturation and modulates the isotype of antibodies induced by a DNA vaccine. Infect Immun 2002; 7: 3939-3943
11. Kraehenbuhl JP. Mucosa-targeted DNA vaccination. Trends Immunol 2001; 12: 646-648
12. Zhao LS, Qin S, Zhou Y, Tang H, Liu Li, Lei BJ. DNA-based vaccination induces humoral and cellular immune responses against hepatitis B virus surface antigen in mice without activation of C-myc. World J Gastroenterol 2000; 6: 239-243
13. Qin S, Zhao LS, Tang H. Detection of NV-HBs/S DNA and C-mycmRNA in mice inoculated with hepatitis B nucleic acid vaccine-NV-HBs/S. Zhonghua Ganzhangbing Zazhi 1999; 1: 67
14. Sambrook J, Russell DW, eds. Molecular Cloning, 3rd Edition, New York, Cold Spring Harbor Laboratory Press 2001; 16: 25-26
15. Qin S, Huang CY, He F, Zhao LS, Liu L. Eukaryotic cell SP2/0 transfection by calcium phosphate method and detection of their expressions. Lett Biotechnol 2000; 2: 115
16. Fearon DT. Innate immunity-beginning to fulfil it’s promise? Nat Immunol 2000; 1: 102-103
17. Monzavi-Karbassi B, Kieber-Emmons T. Current concepts in cancer vaccine strategies. Biotechniques 2001; 1: 170-176
18. Qin S, Zhao LS. Application of DNA-immunization in prevention and treatment of infectious diseases. Zhonghua Chuanranbing Zazhi 1999; 1: 65-66
19. Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 2000; 6: 793-806
20. Robinson HL, Portman TM. DNA vaccines for viral infections: basic studies and applications. Adv Virus Res 2003; 55: 1-74
21. Vecino WH, Morin PM, Agha R, Jacobs WR, Fennelly GJ. Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV. Immun Lett 2002; 3: 197-204
22. Robinson HL. New hope for an AIDS vaccine. Nat Rev Immunol 2002; 4: 239-250
23. Rodriguez F, Harkins S, Silfka MK, Whiton JL. Immunodominance in virus-induced CDB(+)/-T cell responses is dramatically modified by DNA immunization. J Virol 2002; 9: 4251-4259
24. Haupt K, Roggendorf M, Mann K. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp Biol Med (Albany NY) 2002; 4: 227-237

*Edited by Zhang JZ*